Biotech Sector
topic on 2 shows · 3 statements across 2 episodes
Capital Allocators 
the a16z Podcast
3 statements about Biotech Sector, every show
Wong: Doubling drug approvals to 80 will drive massive biotech value creation
“On average, we've been approving forty-ish drugs a year, and if 40 goes to 80, even if you're losing some on pricing, it should be a tremendous amount of value creation.”
Wong: In Q2 2022 biotech stocks sold off even on positive news
“You know, as an example kind of the worst part of the bear market sell-off, this cycle, Q-two of last year, you could have been right on everything, right? Call the event right, Day the news comes out, the stock trades down because it's a source of liquidity l…”
Lowe: Preclinical bio assets lack significant value until reaching clinical trials
“That is because in the bio space value is created in these huge technical milestones in the very beginning where a lot of these services are used. These are preclinical assets in which there's really not too much value until you bring a drug candidate into the…”